← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	2,974	+159	+6%	$422B
2	2 Pfizer PFE $168B	2,928	-116	-4%	$131B
3	3 Amgen AMGN $235B	2,502	+111	+5%	$109B
4	4 Becton Dickinson BDX $52.8B	1,553	-24	-2%	$66.4B
5	5 McKesson MCK $116B	1,347	+27	+2%	$49.7B
6	6 Novo Nordisk NVO $173B	1,306	+110	+9%	$27.4B
7	7 Regeneron Pharmaceuticals REGN $82B	1,177	+13	+1%	$75.1B
8	8 AstraZeneca AZN $259B	1,074	-17	-2%	$33.8B
9	9 Conagra Brands CAG $6.77B	807	-57	-7%	$11.1B
10	10 West Pharmaceutical WST $27B	757	+23	+3%	$25.8B
11	11 Lamb Weston LW $7.47B	751	-30	-4%	$11.8B
12	12 ResMed RMD $34.1B	658	-72	-10%	$13B
13	13 DaVita DVA $12.1B	503	+32	+7%	$7.5B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	435	+7	+2%	$5.66B
15	15 DELISTED CATALENT, INC. CTLT	434	-7	-2%	$9.04B
16	16 Embecta EMBC $365M	373	-26	-7%	$851M
17	17 Inspire Medical Systems INSP $2.03B	364	-43	-11%	$5.65B
18	18 BellRing Brands BRBR $1.05B	329	+18	+6%	$5.06B
19	TWNK 19 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	292	+19	+7%	$4.41B
20	20 Amphastar Pharmaceuticals AMPH $1.12B	255	+10	+4%	$1.47B
21	21 Opko Health OPK $1.2B	225	-4	-2%	$268M
22	22 Medifast MED $135M	223	-13	-6%	$724M
23	23 Dr. Reddy's Laboratories RDY $10.7B	212	+18	+9%	$1.51B
24	24 Accendra Health ACH $20.1M	210	-20	-9%	$1.31B
25	25 Madrigal Pharmaceuticals MDGL $10.6B	205	-3	-1%	$2.54B